Abstract
As one of the basic modalities of oncological therapy, chemotherapy usually leads to permanent consequences. Infertility is one of the most common consequences resulting from irreversible gonadal damage. The potentially effective method of reproductive function protection in women undergoing chemotherapy for haematological malignancy is administration of GnRH analogues during chemotherapy by creating pre-pubertal hormonal milieu. The other useful methods are the cryopreservation of oocytes and ovarian tissue from patients undergoing anti-cancer therapy. The presented OvarOnko project sets the primary target to verify the potential protective effect of GnRH analogues to protect ovarian tissue over the course of three different chemotherapy regimens in female patients with childbearing potential who suffer from Hodgkin’s lymphoma (HL). Another goal of the project is to work out practical conditions and working procedures for the development of the method of the cryopreservation of oocytes and ovarian tissue. The major outcomes of the project will be the verification of efficacy or the lack of efficacy of GnRH analogues in the ovarian function protection and the elaboration of practical conditions and working procedures allowing inclusion of the methods of cryopreservation of oocytes and ovarian tissue in services provided to our patients before anti-cancer treatment. The costs of the two methods of ovarian function protection will be compared. The differences in ovarian response between the patients with HL and non-oncological patients recorded in the register of therapeutic cycles of assisted reproduction will be identified using data-mining methods.
Similar content being viewed by others
References
Lutchman Singh K, Davies M, Chatterjee R (2005) Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 11:69–89
Kim SS (2006) Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril 85(1):1–11
Goswami D, Conway GS (2005) Premature ovarian failure. Hum Reprod Update 11(4):391–410
Ataya K, Rao LV, Laurence E (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 8:86–92
Crha I, Ventruba P, Huser M, Žáková J (2002) Cryo-preservation of semen prior to anticancer therapy—7 years of experiences. Ces Gynek 67:324–328
Tucker M, Morton P, Liebermann J (2004) Human oocyte cryopreservation: a valid alternative to embryo cryopreservation? Eur J Obstet Gynecol Reprod Biol 113(suppl 1):24–27
Borini A, Bonu MA, Coticchio G, Bianchi V, Cattoli M, Flamigni C (2004) Pregnancies and births after oocyte cryopreservation. Fertil Steril 82(3):601–605
Marrs RP, Greene J, Stone BA (2004) Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos. Am J Obstet Gynecol 190(6):1766–1771
Oktay K, Sonmezer M (2004) Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 19(3):477–480
Sonmezer M, Shamonki MI, Oktay K (2005) Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res 322(1):125–132
Donnez J, Dolmans MM, Delmylle D (2004) Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364:1405–1410
Meirow D, Levron J (2005) Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 353(3):318–321
Schilsky R, Sherins R, Hubbard S (1981) Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin’s disease. Am J Med 71:552–556
Blumenfeld Z (2002) Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and-B as markers. Mol Cell Endocrinol 187:93–105
Schweppe KW (2005) Guidelines for the use of GnRH-analogues in the treatment of endometriosis. Zentralbl Gynakol 127(5):308–313
Mardešič T, Šnajderová M (2004) Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 25(1):90–92
Blumenfeld Z (2002) Fertility after treatment for Hodgkin’s disease. Ann Oncol 13(Suppl 1):138–147
Dann EJ, Epelbaum R, Avivi I, Ben Shahar M, Haim N, Rowe JM, Blumenfeld Z (2005) Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 20(8):2247–2249
Huser M, Crha I, Hudecek R, Ventruba P, Zakova J, Smardova L (2006) Gonadal protection with GnRH analogues during chemotherapy-cytotoxic dose derived cohort study (OVARONKO). Gynecol Endocrinol 22(suppl 1):152–153
Johnson J, Tilly JT (2005) Germline stem cells and follicular renewal on the postnatal mammalian ovary. Nature 428:145–150
Gosden RG (2005) Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 34:60–63
Crha I (2004) Reproductive function protection. In: Adam K (ed) General oncology, 2nd edn. Grada, pp 765–784
Schmidt KL, Andersen CY, Loft A, Byskov AG, Ernst E, Andersen AN (2005) Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation. Hum Reprod 20(12):3539–3546
Schrader M, Heicappell R, Muller M (2001) Impact of chemotherapy on male fertility. Onkologie 24:326–330
Acknowledgements
This work is supported by Internal Grant Agency (IGA) of the Ministry of Health of the Czech Republic-No. NR/8469-3.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huser, M., Jurankova, E., Crha, I. et al. Fertility preservation strategies in women undergoing chemotherapy for haematological malignancy. Eur Clinics Obstet Gynaecol 2, 77–81 (2006). https://doi.org/10.1007/s11296-006-0033-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11296-006-0033-x